{"id":"mopv-type-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine virus shedding in stool"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":"very rare, <1 per million doses","effect":"Vaccine-associated paralytic poliomyelitis (VAPP)"}]},"_chembl":{"chemblId":"CHEMBL4297862","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mOPV2 (monovalent oral polio vaccine type 2) contains a weakened live poliovirus type 2 strain that replicates in the intestinal tract, triggering both mucosal IgA antibodies and systemic IgG responses. This oral administration route provides intestinal immunity while also generating systemic protection against poliovirus type 2 infection and disease.","oneSentence":"mOPV type 2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 through mucosal and systemic immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:46.560Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention (poliovirus type 2)"},{"name":"Immunization against poliovirus type 2 in routine childhood vaccination programs"}]},"trialDetails":[{"nctId":"NCT05644184","phase":"PHASE2","title":"Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh","status":"RECRUITING","sponsor":"PATH","startDate":"2023-03-27","conditions":"Poliomyelitis","enrollment":2232},{"nctId":"NCT05654467","phase":"PHASE2","title":"Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama","status":"UNKNOWN","sponsor":"PATH","startDate":"2023-12-05","conditions":"Poliomyelitis","enrollment":1532},{"nctId":"NCT01841671","phase":"PHASE4","title":"Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine","status":"UNKNOWN","sponsor":"University of Chile","startDate":"2013-04","conditions":"Polio","enrollment":570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GSK mOPV type 2"],"phase":"marketed","status":"active","brandName":"mOPV type 2","genericName":"mOPV type 2","companyName":"University of Chile","companyId":"university-of-chile","modality":"Biologic","firstApprovalDate":"","aiSummary":"mOPV type 2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 through mucosal and systemic immunity. Used for Poliomyelitis prevention (poliovirus type 2), Immunization against poliovirus type 2 in routine childhood vaccination programs.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}